ATE251895T1 - Hydrophobe arzneistoffabgabesysteme - Google Patents

Hydrophobe arzneistoffabgabesysteme

Info

Publication number
ATE251895T1
ATE251895T1 AT95912914T AT95912914T ATE251895T1 AT E251895 T1 ATE251895 T1 AT E251895T1 AT 95912914 T AT95912914 T AT 95912914T AT 95912914 T AT95912914 T AT 95912914T AT E251895 T1 ATE251895 T1 AT E251895T1
Authority
AT
Austria
Prior art keywords
drug delivery
delivery systems
hydrophobic drug
dosage form
unit dosage
Prior art date
Application number
AT95912914T
Other languages
English (en)
Inventor
Edward M Rudnic
John A Mccarty
George W Belenduik
Original Assignee
Shire Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Lab Inc filed Critical Shire Lab Inc
Application granted granted Critical
Publication of ATE251895T1 publication Critical patent/ATE251895T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95912914T 1994-03-18 1995-03-15 Hydrophobe arzneistoffabgabesysteme ATE251895T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/210,014 US5430021A (en) 1994-03-18 1994-03-18 Hydrophobic drug delivery systems
PCT/US1995/003212 WO1995025505A1 (en) 1994-03-18 1995-03-15 Hydrophobic drug delivery systems

Publications (1)

Publication Number Publication Date
ATE251895T1 true ATE251895T1 (de) 2003-11-15

Family

ID=22781263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912914T ATE251895T1 (de) 1994-03-18 1995-03-15 Hydrophobe arzneistoffabgabesysteme

Country Status (10)

Country Link
US (1) US5430021A (de)
EP (1) EP0750494B1 (de)
JP (1) JPH09510708A (de)
AT (1) ATE251895T1 (de)
AU (1) AU703950B2 (de)
CA (1) CA2185802C (de)
DE (1) DE69531934T2 (de)
DK (1) DK0750494T3 (de)
ES (1) ES2210286T3 (de)
WO (1) WO1995025505A1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
EP0788346B9 (de) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
JP3471977B2 (ja) * 1995-06-02 2003-12-02 信越化学工業株式会社 液体状可塑剤を用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
DE19521974A1 (de) * 1995-06-16 1996-12-19 Hexal Pharmaforschung Gmbh Pharmazeutische Zubereitung mit Cyclosporin A
WO1997002815A1 (fr) * 1995-07-07 1997-01-30 Nippon Kayaku Kabushiki Kaisha Composition de flutamide
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
CA2302275C (en) 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
EP1036507B1 (de) * 1997-12-03 2007-06-13 Nippon Suisan Kaisha, Ltd. Beschichtungsmittel fuer ofenerhitztes gefriergut enthaltend einen nahrungsmittelkern und eine deckschicht, sowie ein dieses verwendendes nahrungsmittel
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5891888A (en) * 1998-01-14 1999-04-06 Strahl; Robert Charles Physical endurance drink
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
BR9907195A (pt) * 1998-01-22 2000-10-10 Abbott Lab " formulações de tiagabina de liberação prolongada com efeitos colaterais reduzidos "
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
US5869704A (en) * 1998-08-24 1999-02-09 Eastman Chemical Company Water-dispersible or water-soluble D-tocotrienol compounds and methods for making therefor
US6638522B1 (en) 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
ATE404172T1 (de) 1998-12-30 2008-08-15 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6384248B1 (en) * 2000-08-17 2002-05-07 Fan Tech Ltd Meadowfoam based sorbitan esters
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
DK1345593T3 (da) * 2000-12-27 2007-12-10 Ares Trading Sa Lipidmikropartikler ved kryogen mikronisering
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
KR20040098023A (ko) * 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2007517908A (ja) * 2004-01-16 2007-07-05 グラクソ　グループ　リミテッド 腸溶性ポリマー中における脂質基材の処方のカプセル封入
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US20050260303A1 (en) * 2004-03-08 2005-11-24 Tritch Daniel L Sports drink
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
EP1765305A4 (de) * 2004-07-09 2008-06-04 Drugtech Corp Kontrollierte phasenzusammensetzungstechnologie als verbessertes verfahren zum schutz von arzneimitteln
EP1781257B1 (de) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmazeutische formulierungen mit mikropartikeln oder nanopartikeln eines zufuhrmittels
EP1827393A4 (de) * 2004-12-09 2012-04-18 Insys Therapeutics Inc Bei raumtemperatur stabile dronabinol-formulierungen
GB2426703B (en) * 2005-05-31 2007-09-19 Malvern Cosmeceutics Ltd Compositions
JP2009502841A (ja) * 2005-07-26 2009-01-29 グラクソ グループ リミテッド 脂質をベースにした製剤の腸溶性ポリマー中へのカプセル化
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
PL2268160T3 (pl) * 2008-03-20 2013-05-31 Virun Inc Emulsje zawierające pochodną PEG tokoferolu
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US10210216B2 (en) * 2009-12-18 2019-02-19 Sybase, Inc. Dynamic attributes for mobile business objects
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
ME03376B (de) 2010-05-20 2020-01-20 Array Biopharma Inc Makrocyclische verbindungen als trk-kinasehemmer
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
WO2012033478A1 (en) * 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US10874122B2 (en) 2012-02-10 2020-12-29 Virun, Inc. Beverage compositions containing non-polar compounds
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
EP3368039A1 (de) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Punktmutationen bei trk-inhibitor-resistentem krebs und zugehörige verfahren
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
EP3458456B1 (de) 2016-05-18 2020-11-25 Loxo Oncology Inc. Herstellung von (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018174938A1 (en) 2017-03-23 2018-09-27 Virun, Inc. Stable dry powders and emulsions containing probiotics and mucoadhesive protein
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
EP3740490A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrazol[3,4-d]pyridin-verbindungen als ret-kinasehemmer
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
JP2547995B2 (ja) * 1987-01-26 1996-10-30 昭和電工株式会社 反すう動物用粒剤及びその製造法
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
US5185147A (en) * 1988-08-19 1993-02-09 Cellular Products, Inc. Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
DE3838094A1 (de) * 1988-11-10 1990-05-17 Nordmark Arzneimittel Gmbh Feste pharmazeutische retardform
US4971804A (en) * 1989-02-02 1990-11-20 Warner-Lambert Company Water dispersible gemfibrozil compositions
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
JPH048366A (ja) * 1990-04-26 1992-01-13 Dainichiseika Color & Chem Mfg Co Ltd 顆粒状芳香脱臭剤
EP0459516A1 (de) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
US5234695A (en) * 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery

Also Published As

Publication number Publication date
CA2185802A1 (en) 1995-09-28
DK0750494T3 (da) 2004-01-19
US5430021A (en) 1995-07-04
WO1995025505A1 (en) 1995-09-28
DE69531934D1 (de) 2003-11-20
ES2210286T3 (es) 2004-07-01
CA2185802C (en) 2009-12-22
AU703950B2 (en) 1999-04-01
EP0750494A1 (de) 1997-01-02
DE69531934T2 (de) 2004-09-02
JPH09510708A (ja) 1997-10-28
AU1992595A (en) 1995-10-09
EP0750494A4 (de) 1998-05-20
EP0750494B1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
DE69531934D1 (de) Hydrophobe arzneistoffabgabesysteme
CA2103306A1 (en) Extrudable compositions for topical or transdermal drug delivery
DE69805001D1 (de) Osmotische darreichungsform mit zwei mantelschichten
KR950703383A (ko) 초음파 경피약제전달 시스템(ultrasonic transdermal drug delivery system)
FR2740686B1 (fr) Formulation pharmaceutique lyophilisee stable
DE19882286T1 (de) Intravesikale Medikamentenabgabesysteme
ATE201989T1 (de) Arzneimittel mit kontrollierter wirkstoffabgabe
NO981746D0 (no) Utlevering av biologisk aktive polypeptider
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
DK205889D0 (da) Vandbaseret farmaceutisk overtraeksmateriale til doseringsformer
MA26456A1 (fr) Formulations pharmaceutiques pour la distribution prolongee de medicament.
DE3586713D1 (de) Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
DE69723303D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe
AU5710896A (en) Intrapulmonary delivery of hematopoietic drug
ES2170501T3 (es) Composicion farmaceutica antivirica que comprende acido glicirrizico y al menos una proteina que posee actividad antivirica.
AU6712090A (en) Drug delivery systems and matrix therefor
FI972949A0 (fi) Lääkemuoto kollagenaasin vapauttamiseksi haavoihin ja sen valmistusmenetelmiä
TR199600583A2 (tr) Farmasötik aktiviteye sahip -amino asitlerin tolere edilebilirliginin arttirilmasi.
IT9003728A0 (it) Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazionee formulazioni farmaceutiche che li contengono.
DK89592D0 (da) Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
WO1992019209A3 (en) Taste-masked medicaments and their preparation
FR2716661B1 (fr) Chariots de stockage et notamment échelles pâtissières et de laboratoire.
FI944229A0 (fi) Astyylisalisyylihappoon tai sen suoloihin perustuva puristettu farmaseuttinen annosmuoto oraalista antoa varten ja menetelmä sen valmistamiseksi
CA2184395A1 (en) Effective dosage form for antiepileptic drugs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties